Revolution Medicines Inc Market Cap ($40.32 Billion)
Market Cap & Net Worth: Revolution Medicines Inc (RVMD)
Revolution Medicines Inc market cap. Revolution Medicines Inc (NASDAQ:RVMD) has a market capitalization of $40.32 Billion ($40.32 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #656 globally and #319 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Revolution Medicines Inc's stock price $188.17 by its total outstanding shares 214336418 (214.34 Million). Also see cash flow conversion of Revolution Medicines Inc for how efficiently the company converts equity into cash flow.
Revolution Medicines Inc Market Cap History (2020–2026)
Revolution Medicines Inc market cap history from 2020 to 2026. Data shows growth from $8.49 Billion to $40.33 Billion (32.14% CAGR). Check Revolution Medicines Inc stock price for real-time trading data and today's change.
Index Memberships
Revolution Medicines Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 1.55% | #11 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.10% | #93 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 2.20% | #8 of 263 |
Weight: Revolution Medicines Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Revolution Medicines Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Revolution Medicines Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Revolution Medicines Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
530.84x
Revolution Medicines Inc's market cap is 530.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $8.49 Billion | $42.98 Million | -$108.16 Million | 197.42x | N/A |
| 2021 | $5.39 Billion | $29.39 Million | -$187.09 Million | 183.56x | N/A |
| 2022 | $5.11 Billion | $35.38 Million | -$248.71 Million | 144.30x | N/A |
| 2023 | $6.15 Billion | $11.58 Million | -$436.37 Million | 530.84x | N/A |
Competitor Companies of RVMD by Market Capitalization
Companies near Revolution Medicines Inc in the global market cap rankings as of November 4, 2026. Also see total assets of Revolution Medicines Inc for a full breakdown of the balance sheet.
Key companies related to Revolution Medicines Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Revolution Medicines Inc (2020–2026)
Market capitalization of Revolution Medicines Inc from 2020 to today. Between 2020 and today, Revolution Medicines Inc's market cap moved from $8.49 Billion to $ 40.33 Billion, with a yearly change of 32.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $40.33 Billion | +136.25% |
| 2025 | $17.07 Billion | +82.10% |
| 2024 | $9.38 Billion | +52.51% |
| 2023 | $6.15 Billion | +20.40% |
| 2022 | $5.11 Billion | -5.36% |
| 2021 | $5.39 Billion | -36.42% |
| 2020 | $8.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Revolution Medicines Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.32 Billion USD |
| MoneyControl | $40.32 Billion USD |
| MarketWatch | $40.32 Billion USD |
| marketcap.company | $40.32 Billion USD |
| Reuters | $40.32 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more